Abstract
The measurement errors associated with two techniques for brain atrophy assessment in multiple sclerosis (MS) were estimated. The measurement error of a semiautomated, nonnormalized technique with partial brain coverage was about twofold higher than that of a fully automated, normalized technique with full brain coverage (Structural Image Evaluation of Normalized Atrophy software [SIENA]). As shown by the analysis of data from a clinical trial of glatiramer acetate, the use of SIENA increases the study power to detect a treatment effect on brain volume changes in MS patients.
Publication types
-
Comparative Study
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Atrophy / complications
-
Atrophy / diagnosis*
-
Atrophy / drug therapy
-
Brain / pathology*
-
Brain Diseases / complications
-
Brain Diseases / diagnosis*
-
Brain Diseases / drug therapy
-
Double-Blind Method
-
Glatiramer Acetate
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Magnetic Resonance Imaging / methods*
-
Magnetic Resonance Imaging / statistics & numerical data*
-
Multiple Sclerosis / complications*
-
Multiple Sclerosis / drug therapy
-
Peptides / therapeutic use
-
Predictive Value of Tests
-
Randomized Controlled Trials as Topic / statistics & numerical data
-
Reproducibility of Results
-
Sensitivity and Specificity
-
Statistics as Topic / methods
Substances
-
Immunosuppressive Agents
-
Peptides
-
Glatiramer Acetate